Clinical Trials Arena reports that Merz Therapeutics has finished recruiting participants for MINT-C and MINT-E. These global Phase III studies evaluate Xeomin for migraine prevention in adults.
Trial conduct and operationsAI summary
Read at Clinical Trials Arena